MCID: DLS001
MIFTS: 41

Delusional Disorder malady

Categories: Mental diseases

Aliases & Classifications for Delusional Disorder

Aliases & Descriptions for Delusional Disorder:

Name: Delusional Disorder 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:778
ICD10 33 F22 F22.0
ICD9CM 35 297.1
MeSH 42 D012563
NCIt 47 C94379
SNOMED-CT 64 192330005 48500005
UMLS 69 C0011251

Summaries for Delusional Disorder

Disease Ontology : 12 A psychotic disorder that involves an uncommon psychiatric condition in which patients present with circumscribed symptoms of non-bizarre delusions, but with the absence of prominent hallucinations and no thought disorder, mood disorder, or significant flattening effect.

MalaCards based summary : Delusional Disorder is related to schizophrenia and personality disorder. An important gene associated with Delusional Disorder is DRD2 (Dopamine Receptor D2), and among its related pathways/superpathways are Beta-Adrenergic Signaling and Circadian entrainment. The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include eye, pituitary and brain, and related phenotype is Decreased shRNA abundance (Z-score < -2).

Wikipedia : 71 Delusional disorder is a mental illness in which the patient presents with delusions, but with no... more...

Related Diseases for Delusional Disorder

Diseases related to Delusional Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 67)
id Related Disease Score Top Affiliating Genes
1 schizophrenia 30.7 DRD2 DRD3 DRD4 TH
2 personality disorder 29.4 DRD2 DRD3 DRD4
3 capgras syndrome 11.1
4 paranoid schizophrenia 10.5
5 teratoma with malignant transformation 10.1 DRD2 DRD3
6 ischemic neuropathy 10.1 DRD2 DRD3
7 usher syndrome 10.1 DRD2 DRD3
8 transmitted_by 10.1 DRD2 DRD3
9 hypoglycemia 10.0 DRD2 DRD3
10 18p deletion syndrome 10.0 DRD2 DRD4
11 colorectal adenocarcinoma 10.0 DRD2 DRD4
12 rectosigmoid junction neoplasm 10.0 DRD2 DRD4
13 suppurative periapical periodontitis 10.0 DRD2 DRD3 TH
14 cavernous hemangioma 10.0 DRD2 DRD3 TH
15 autism 19 10.0 DRD2 TH
16 hemochromatosis, type 2a 10.0 DRD2 DRD3 TH
17 brain glioblastoma multiforme 9.9 DRD2 DRD3 TH
18 body dysmorphic disorder 9.9
19 carotid stenosis 9.9 DRD2 DRD4
20 alzheimer disease 17 9.9 DRD3 DRD4
21 mastitis 9.9 DRD4 HLA-A
22 aortic valve disease 2 9.9 DRD2 DRD4
23 intracranial aneurysm 9.9 DRD2 DRD3 DRD4
24 pyromania 9.9 DRD2 DRD3 DRD4
25 c8 deficiency, type ii 9.9 DRD2 DRD3 DRD4
26 cecal benign neoplasm 9.9 DRD2 DRD3 DRD4
27 mucinous adenocarcinoma 9.8 DRD2 DRD3 DRD4
28 alopecia 9.8 DRD2 DRD3 DRD4
29 hypereosinophilic syndrome 9.8 DRD2 DRD3 DRD4
30 retinoblastoma 9.8 DRD2 DRD3 DRD4
31 microcephaly 13, primary, autosomal recessive 9.8 DRD2 DRD3 DRD4
32 preeclampsia/eclampsia 5 9.8 DRD2 DRD3 DRD4
33 benign epilepsy with centrotemporal spikes 9.8 DRD2 DRD4 TH
34 paraphilia disorder 9.8 DRD2 DRD3 DRD4
35 schizotypal personality disorder 9.8
36 early-onset schizophrenia 9.8
37 anorexia nervosa 9.8
38 dementia 9.8
39 hepatitis d 9.8 DRD2 DRD4
40 cytomegalic congenital adrenal hypoplasia 9.7 DRD2 DRD3 DRD4 TH
41 ellis-van creveld syndrome 9.6 DRD2 DRD3 DRD4 TH
42 trimethylaminuria 9.6
43 alcohol dependence 9.6
44 hyperprolactinemia 9.6
45 phenylketonuria 9.6
46 alcohol abuse 9.6
47 bipolar disorder 9.6
48 charcot-marie-tooth disease 9.6
49 hydrocephalus 9.6
50 sleep apnea 9.6

Comorbidity relations with Delusional Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Alzheimer Disease
Anxiety Disorder Deficiency Anemia
Dysthymic Disorder Hypothyroidism
Paranoid Personality Disorder Paranoid Schizophrenia
Parkinson Disease, Late-Onset Schizophreniform Disorder

Graphical network of the top 20 diseases related to Delusional Disorder:



Diseases related to Delusional Disorder

Symptoms & Phenotypes for Delusional Disorder

GenomeRNAi Phenotypes related to Delusional Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 8.8 DRD3
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 8.8 DRD3 DRD4

Drugs & Therapeutics for Delusional Disorder

Drugs for Delusional Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
2
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2 106266-06-2 5073
3
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2 132539-06-1 4585
4
Donepezil Approved Phase 4,Phase 3 120014-06-4 3152
5
Ziprasidone Approved Phase 4 146939-27-7 60854
6
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
7
Oxcarbazepine Approved Phase 4 28721-07-5 34312
8
Galantamine Approved Phase 4 357-70-0 9651 908828, 9651
9
Nicergoline Approved Phase 4 27848-84-6 34040
10 Piracetam Approved Phase 4 7491-74-9
11
Citalopram Approved Phase 4,Phase 2 59729-33-8 2771
12
Armodafinil Approved, Investigational Phase 4 112111-43-0
13
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
14
Cycloserine Approved Phase 4,Phase 3 68-41-7 401 6234
15
Acetaminophen Approved Phase 4 103-90-2 1983
16
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
17
Sulfamethazine Approved, Vet_approved Phase 4 57-68-1 5327
18
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
19 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
20 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
21 Dopamine Agents Phase 4,Phase 3,Phase 2
22 Dopamine Antagonists Phase 4,Phase 3,Phase 2
23 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25
Serotonin Phase 4,Phase 3,Phase 2 50-67-9 5202
26 Serotonin Agents Phase 4,Phase 3,Phase 2
27 Serotonin Antagonists Phase 4,Phase 3,Phase 2
28 Tranquilizing Agents Phase 4,Phase 3,Phase 2
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Autonomic Agents Phase 4,Phase 3,Phase 2
31 Cholinergic Agents Phase 4,Phase 3
32 Cholinesterase Inhibitors Phase 4,Phase 3
33 Nootropic Agents Phase 4,Phase 3
34 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2
35 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2
36 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
37 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
38 Analgesics Phase 4,Phase 1,Phase 2
39 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
40 Anticonvulsants Phase 4
41 Antimanic Agents Phase 4,Phase 2
42 Cytochrome P-450 CYP3A Inducers Phase 4
43 Diuretics, Potassium Sparing Phase 4
44 Sodium Channel Blockers Phase 4
45 Adrenergic Agents Phase 4
46 Adrenergic alpha-Antagonists Phase 4
47 Adrenergic Antagonists Phase 4
48 Vasodilator Agents Phase 4
49 Antidepressive Agents Phase 4,Phase 3,Phase 2
50 Antidepressive Agents, Second-Generation Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 108)
id Name Status NCT ID Phase
1 A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis Completed NCT00644800 Phase 4
2 The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States. Completed NCT00154323 Phase 4
3 An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders Completed NCT01855074 Phase 4
4 An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment Completed NCT00526877 Phase 4
5 An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00992407 Phase 4
6 Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine Completed NCT01009476 Phase 4
7 A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression Completed NCT01814085 Phase 4
8 An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia Completed NCT00269919 Phase 4
9 A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode Completed NCT00378092 Phase 4
10 Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia Completed NCT01726335 Phase 4
11 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed NCT01023672 Phase 4
12 A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia Completed NCT01577160 Phase 4
13 PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia Completed NCT00761189 Phase 4
14 Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants Completed NCT01387542 Phase 4
15 Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission Completed NCT00761579 Phase 4
16 Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants Completed NCT00784238 Phase 4
17 A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia Completed NCT00915512 Phase 4
18 An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia Completed NCT00757705 Phase 4
19 A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone Completed NCT01010776 Phase 4
20 Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years Completed NCT01362439 Phase 4
21 Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia Completed NCT00742079 Phase 4
22 D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions Recruiting NCT01981759 Phase 4
23 Integrated Care in Psychotic Disorders With Severe Mental Illness Recruiting NCT01888627 Phase 4
24 Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine Recruiting NCT02505477 Phase 4
25 Melatonin for Delirium Prophylaxis Not yet recruiting NCT02282241 Phase 4
26 Schizophrenic Patients in Integrated Care Terminated NCT00681629 Phase 4
27 An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia Terminated NCT01894984 Phase 4
28 A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication Terminated NCT00256997 Phase 4
29 Observational Study Of Donepezil In Routine Clinical Practice Terminated NCT00843115 Phase 4
30 Trial of Cognitive Behavioral Therapy for Schizophrenia Unknown status NCT00300651 Phase 3
31 Donepezil Treatment of Psychotic Symptoms in Dementia Patients Unknown status NCT00190021 Phase 3
32 Study of Pharmacotherapy of Psychotic Depression Completed NCT00056472 Phase 3
33 Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder Completed NCT01888107 Phase 3
34 A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression Completed NCT00130676 Phase 3
35 A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression Completed NCT00128479 Phase 3
36 An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression Completed NCT00128505 Phase 3
37 A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression Completed NCT00208156 Phase 3
38 An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression Completed NCT00146523 Phase 3
39 A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00249158 Phase 3
40 A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia Completed NCT00604279 Phase 3
41 Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia Completed NCT01662648 Phase 3
42 An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia Completed NCT01009047 Phase 3
43 An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia Completed NCT00566631 Phase 3
44 An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia Completed NCT01299389 Phase 3
45 A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia Completed NCT01541371 Phase 3
46 Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants Completed NCT00419146 Phase 2, Phase 3
47 Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type Completed NCT01438060 Phase 3
48 An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia Active, not recruiting NCT00460512 Phase 3
49 A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease Terminated NCT00287742 Phase 3
50 A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease Terminated NCT00912288 Phase 3

Search NIH Clinical Center for Delusional Disorder

Genetic Tests for Delusional Disorder

Anatomical Context for Delusional Disorder

MalaCards organs/tissues related to Delusional Disorder:

39
Eye, Pituitary, Brain, Liver

Publications for Delusional Disorder

Articles related to Delusional Disorder:

(show top 50) (show all 175)
id Title Authors Year
1
What is the Evidence for Treating Delusional Disorder? ( 27712246 )
2016
2
Aripiprazole-induced Hyperprolactinemia in a Young Female with Delusional Disorder. ( 27335526 )
2016
3
A Systematic Review on the Pharmacological Treatment of Delusional Disorder. ( 27811554 )
2016
4
Characteristics and clinical correlates of dimensions of delusional experience in schizophrenia and delusional disorder. ( 27261418 )
2016
5
Clinical Presentation and Course of Persistent Delusional Disorder: Data From a Tertiary Care Center in India. ( 27247844 )
2016
6
Delusional disorder and schizophrenia: a comparative study across multiple domains. ( 27468631 )
2016
7
Folie a deux and delusional disorder by proxy: an atypical presentation. ( 27245561 )
2016
8
Structural and functional brain changes in delusional disorder. ( 26382955 )
2016
9
Letter to the Editor: Comparing delusional disorder and schizophrenia: a comment on Hui et al. (2015). ( 26690961 )
2016
10
Antipsychotic response in delusional disorder and schizophrenia: a prospective cohort study. ( 27388104 )
2016
11
Unexpected subthreshold autism spectrum in a 25-year-old male stalker hospitalized for delusional disorder: a case report. ( 26031384 )
2015
12
A dimensional comparison between delusional disorder, schizophrenia and schizoaffective disorder. ( 26585220 )
2015
13
Therapeutic approach to delusional disorder based on psychopathological complexity: proposal for a decision model. ( 25679132 )
2015
14
Letter to the Editor: Comparing delusional disorder and schizophrenia: a comment on Hui et al. (2015) - a reply. ( 26691196 )
2015
15
Treatments for delusional disorder. ( 25997589 )
2015
16
Delusional disorder and schizophrenia: a comparison of the neurocognitive and clinical characteristics in first-episode patients. ( 26036591 )
2015
17
Treatments for Delusional Disorder. ( 26209547 )
2015
18
The prevalence of delusional disorder in prison. ( 25770283 )
2015
19
Normal pressure hydrocephalus presenting as delusional disorder. ( 26257493 )
2015
20
Paranoid delusional disorder follows social anxiety disorder in a long-term case series: evolutionary perspective. ( 26034873 )
2015
21
Delusional Disorder over the Reproductive Life Span: The Potential Influence of Menopause on the Clinical Course. ( 26600949 )
2015
22
Phenotypic cognitive impairment in late-onset delusional disorder. ( 24524668 )
2014
23
Delusional Disorder as a Partial Psychosis. ( 24421383 )
2014
24
Aripiprazole in difficult-to-treat delusional disorder with co-morbid epilepsy. ( 24779650 )
2014
25
Supersensitivity psychosis and its response to asenapine in a patient with delusional disorder. ( 25478273 )
2014
26
Delusional disorder: no gender differences in age at onset, suicidal ideation, or suicidal behavior. ( 24554277 )
2014
27
Delusional disorder: an unusual presentation. ( 25336783 )
2014
28
Russell's sign in persistent delusional disorder: a case report. ( 25093783 )
2014
29
Sexual Feelings Toward the Therapist Among Patients with Borderline Personality Disorder: A Case of Erotomanic Delusional Disorder. ( 25391585 )
2014
30
Psy-feld: An Innovative Didactic Using the TV Show Seinfeld to Teach Delusional Disorder Subtypes. ( 25410045 )
2014
31
Suicidal ideation and suicidal behaviour in delusional disorder: a clinical overview. ( 24829903 )
2014
32
Atypical delusional content in a case of persistent delusional disorder: freud revisited. ( 25336780 )
2014
33
Monosymptomatic Hypochondriacal Psychosis (somatic delusional disorder): a report of two cases. ( 23595526 )
2013
34
Low-dose quetiapine for the treatment of delusional disorder in a patient with Von Hippel-Lindau disease. ( 24026746 )
2013
35
Delusional disorder, somatic type: olfactory reference syndrome in a patient with delusional trimethylaminuria. ( 23719328 )
2013
36
Reproductive variables and gynaecological service use in delusional disorder outpatients. ( 24378254 )
2013
37
Argyrophilic grain disease as a neurodegenerative substrate in late-onset schizophrenia and delusional disorders. ( 24272318 )
2013
38
Effectiveness of low-dose milnacipran for a patient suffering from pain disorder with delusional disorder (somatic type) in the orofacial region. ( 23909967 )
2013
39
Deficits in executive and memory processes in delusional disorder: a case-control study. ( 23844005 )
2013
40
Empirical redefinition of delusional disorder and its phenomenology: the DELIREMP study. ( 23021895 )
2013
41
Delayed-onset post-stroke delusional disorder: a case report. ( 23619082 )
2013
42
A descriptive retrospective study of the treatment and outpatient service use in a clinical group of delusional disorder patients. ( 23490496 )
2013
43
Delusional disorder and oncology: review of the literature and case report. ( 24066407 )
2013
44
Comparative efficacy and acceptability of existing pharmacotherapies for delusional disorder: a retrospective case series and review of the literature. ( 23771191 )
2013
45
Prevalence of premorbid personality disorder and its clinical correlates in patients with delusional disorder. ( 23993136 )
2013
46
The clinical and sociodemographic profile of persistent delusional disorder. ( 22441422 )
2012
47
Delusional disorders--are they simply paranoid schizophrenia? ( 21078814 )
2012
48
Imprisonment, alcohol dependence and risk of delusional disorder: a cross-sectional study. ( 22608012 )
2012
49
Clinical course and personality in reactive, compared with nonreactive, delusional disorder. ( 22480586 )
2012
50
Neuropsychological research in delusional disorder: a comprehensive review. ( 22269940 )
2012

Variations for Delusional Disorder

Expression for Delusional Disorder

Search GEO for disease gene expression data for Delusional Disorder.

Pathways for Delusional Disorder

GO Terms for Delusional Disorder

Cellular components related to Delusional Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.26 DRD2 DRD3 DRD4 HLA-A
2 endocytic vesicle GO:0030139 8.62 DRD2 DRD3

Biological processes related to Delusional Disorder according to GeneCards Suite gene sharing:

(show all 38)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.86 DRD2 DRD3 PNP TH
2 response to ethanol GO:0045471 9.77 DRD2 DRD3 TH
3 locomotory behavior GO:0007626 9.75 DRD2 DRD3 TH
4 social behavior GO:0035176 9.69 DRD3 DRD4 TH
5 cellular calcium ion homeostasis GO:0006874 9.68 DRD3 DRD4
6 learning GO:0007612 9.67 DRD3 TH
7 circadian regulation of gene expression GO:0032922 9.67 DRD2 DRD3
8 visual learning GO:0008542 9.67 DRD2 DRD3
9 response to nicotine GO:0035094 9.66 DRD2 TH
10 response to cocaine GO:0042220 9.66 DRD2 DRD3
11 pigmentation GO:0043473 9.65 DRD2 TH
12 negative regulation of protein kinase B signaling GO:0051898 9.65 DRD2 DRD3
13 positive regulation of cytokinesis GO:0032467 9.65 DRD2 DRD3
14 negative regulation of adenylate cyclase activity GO:0007194 9.65 DRD2 DRD3 DRD4
15 negative regulation of blood pressure GO:0045776 9.64 DRD2 DRD3
16 response to morphine GO:0043278 9.64 DRD2 DRD3
17 response to light stimulus GO:0009416 9.63 DRD2 TH
18 regulation of dopamine secretion GO:0014059 9.63 DRD2 DRD3
19 arachidonic acid secretion GO:0050482 9.63 DRD2 DRD3 DRD4
20 behavioral response to ethanol GO:0048149 9.62 DRD2 DRD4
21 prepulse inhibition GO:0060134 9.62 DRD2 DRD3
22 positive regulation of renal sodium excretion GO:0035815 9.61 DRD2 DRD3
23 negative regulation of voltage-gated calcium channel activity GO:1901386 9.61 DRD2 DRD4
24 behavioral response to cocaine GO:0048148 9.61 DRD2 DRD3 DRD4
25 G-protein coupled receptor internalization GO:0002031 9.6 DRD2 DRD3
26 regulation of cAMP metabolic process GO:0030814 9.58 DRD2 DRD3
27 dopamine receptor signaling pathway GO:0007212 9.58 DRD2 DRD3 DRD4
28 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.57 DRD2 DRD3
29 negative regulation of dopamine receptor signaling pathway GO:0060160 9.55 DRD2 DRD3
30 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.54 DRD2 DRD4
31 synaptic transmission, dopaminergic GO:0001963 9.54 DRD2 DRD3 TH
32 acid secretion GO:0046717 9.52 DRD2 DRD3
33 dopamine metabolic process GO:0042417 9.5 DRD2 DRD3 DRD4
34 regulation of locomotion involved in locomotory behavior GO:0090325 9.49 DRD2 DRD3
35 negative regulation of protein secretion GO:0050709 9.43 DRD2 DRD3 DRD4
36 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.33 DRD2 DRD3 DRD4
37 response to histamine GO:0034776 9.13 DRD2 DRD3 DRD4
38 response to amphetamine GO:0001975 8.92 DRD2 DRD3 DRD4 TH

Molecular functions related to Delusional Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.56 DRD2 DRD3 DRD4 PNP
2 signal transducer activity GO:0004871 9.5 DRD2 DRD3 DRD4
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.33 DRD2 DRD3 DRD4
4 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD2 DRD3 DRD4
5 dopamine binding GO:0035240 8.92 DRD2 DRD3 DRD4 TH

Sources for Delusional Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....